Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy for the Management of Peritoneal Carcinomatosis from Ovarian Cancer: A Preliminary Single-Center Experience from Saudi Arabia

Metadatas

Author
Date

January 1, 2017

Discipline
type
Language
Organization

Knowledge Unlatched

License

https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode



Cite this document

osama alomar, « Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy for the Management of Peritoneal Carcinomatosis from Ovarian Cancer: A Preliminary Single-Center Experience from Saudi Arabia », Open Research Library, ID : 10.26226/morressier.5d2ee8ea1e09a6f49485abae


Metrics


Share / Export

Abstract 0

Background: Ovarian cancer is regarded as the leading cause of cancer-related death among all types of gynecologic malignancy. Unfortunately, around two thirds of patients present to clinical attention with advanced disease stage in the form of peritoneal carcinomatosis (PC) or distant metastasis, and the associated five-year survival is very poor. Aim: To report our pilot single-center experience with cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) for management of peritoneal carcinomatosis (PC) from ovarian cancer. Methods. Twenty seven patients (n=27) were retrospectively analyzed for perioperative details. Results. The mean age was 53 years, whereas the mean body mass index (BMI) was 33.1 kg/m2. The vast majority of patients had serous adenocarcinoma (92.6%), stage III disease (77.8%) and primary advanced disease presentation (59.3%). Cytoreduction completeness (CC-0) and (CC-1) were achieved in 556% and 44.6%, respectively. The median peritoneal cancer index (PCI) was 11. Combination cisplatin + doxorubicin HIPEC chemotherapy was used in the vast majority of patients (70.4%). The median operative time, estimated blood loss, and hospital stay were 8 hours, 1100 mL and 12 days, respectively. Major postoperative Clavien-Dindo grade III/IV complications occurred in 5 patients (18.5%) and none developed HIPEC chemotherapy-related toxicities. The median follow-up time was 16 months. A total of 8 patients (29.6%) experienced recurrence. A total of 18 patients were alive either with disease (n=9, 33.3%) or without disease (n=17, 63%); only one patient died. Patients with CC-0 and PCI10. Conclusion: CRS plus HIPEC is feasible, safe and offers favorable therapeutic benefits in patients with PC arising from ovarian cancer.

From the same authors

On the same subjects

Similar documents

Within the same disciplines